# Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

> **NCT05991284** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Ziekenhuis Oost-Limburg** · enrollment: 84 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Functional Mitral Regurgitation

## Interventions

- **DRUG:** Sacubitril-valsartan
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05991284
- **Lead sponsor:** Ziekenhuis Oost-Limburg
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2025-09-22
- **Final completion:** 2026-05-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05991284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05991284, "Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05991284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*